Cover Image
市場調查報告書

淋菌感染疾病:開發平台分析

Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 302490
出版日期 內容資訊 英文 98 Pages
訂單完成後即時交付
價格
Back to Top
淋菌感染疾病:開發平台分析 Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 98 Pages
簡介

淋病是由淋菌所引起的表面黏膜感染症。淋菌會藉由性接觸或分娩傳染。而發生排尿困難、月經中期出血、性交疼痛、下腹疼痛、發燒、惡寒、噁心、嘔吐等症狀。

本報告提供淋菌感染疾病治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

淋菌感染疾病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Adenium Biotech ApS
  • Allergan Plc
  • BioDiem Ltd
  • Biolytics Pharma
  • Debiopharm International S.A.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Sarepta Therapeutics, Inc.
  • 大日本住友製藥
  • Vertex Pharmaceuticals Incorporated

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections
  • Arenicin
  • BDM-I
  • Biologic for Neisseria Gonorrhoeae Infection
  • Cribrostatin-6
  • dalbavancin
  • Debio-1453
  • gepotidacin mesylate
  • gonorrhoeae vaccine
  • gonorrhoeae vaccine
  • gonorrhoeae vaccine
  • SM-295291
  • SM-369926
  • Small Molecule to Inhibit Tubulin for Oncology and Neisseria Gonorrhoeae Infections
  • Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections
  • Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections
  • VT-12008911
  • zoliflodacin

最新開發平台趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8293IDB

Summary

Global Markets Direct's, 'Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016', provides an overview of the Neisseria gonorrhoeae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neisseria gonorrhoeae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neisseria gonorrhoeae Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Neisseria gonorrhoeae Infections
  • The report reviews pipeline therapeutics for Neisseria gonorrhoeae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Neisseria gonorrhoeae Infections therapeutics and enlists all their major and minor projects
  • The report assesses Neisseria gonorrhoeae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Neisseria gonorrhoeae Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Neisseria gonorrhoeae Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neisseria gonorrhoeae Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neisseria gonorrhoeae Infections Overview
  • Therapeutics Development
    • Pipeline Products for Neisseria gonorrhoeae Infections - Overview
    • Pipeline Products for Neisseria gonorrhoeae Infections - Comparative Analysis
  • Neisseria gonorrhoeae Infections - Therapeutics under Development by Companies
  • Neisseria gonorrhoeae Infections - Therapeutics under Investigation by Universities/Institutes
  • Neisseria gonorrhoeae Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Neisseria gonorrhoeae Infections - Products under Development by Companies
  • Neisseria gonorrhoeae Infections - Products under Investigation by Universities/Institutes
  • Neisseria gonorrhoeae Infections - Companies Involved in Therapeutics Development
    • Allergan Plc
    • BioDiem Ltd
    • Biolytics Pharma
    • Debiopharm International SA
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Merck & Co., Inc.
    • Paratek Pharmaceuticals, Inc.
    • Recce Pty Ltd
    • Redx Pharma Plc
    • Sarepta Therapeutics, Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
  • Neisseria gonorrhoeae Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BDM-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Neisseria Gonorrhoeae Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dalbavancin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Debio-1453 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • edodekin alfa SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gepotidacin mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neisseria gonorrhoeae (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neisseria gonorrhoeae vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omadacycline tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Neisseria gonorrhoeae Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-295291 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-369926 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Bacterial Cell Wall for Gonorrhoea and Tuberculosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit DNA Gyrase for Neisseria Gonorrhoeae Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Tubulin for Oncology and Neisseria Gonorrhoeae Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VT-12008911 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neisseria gonorrhoeae Infections - Dormant Projects
  • Neisseria gonorrhoeae Infections - Discontinued Products
  • Neisseria gonorrhoeae Infections - Product Development Milestones
    • Featured News & Press Releases
      • Dec 22, 2015: Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents
      • Sep 10, 2015: Cempra to Present Data From Antibiotic Drug Solithromycin at ICAAC/ICC 2015 Meeting
      • Nov 19, 2014: Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies
      • Sep 09, 2014: Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
      • Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection
      • Apr 26, 2013: Cempra To Present Data On Solithromycin's Potential Against Urogenital Infections And Multidrug-Resistant Pathogens At ECCMID
      • Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I
      • Mar 31, 2012: Cempra's Solithromycin Demonstrates In Vitro Activity Against Antibiotic-Resistant Neisseria Gonorrhoeae Isolates
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Neisseria gonorrhoeae Infections, H2 2016
  • Number of Products under Development for Neisseria gonorrhoeae Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Neisseria gonorrhoeae Infections - Pipeline by Allergan Plc, H2 2016
  • Neisseria gonorrhoeae Infections - Pipeline by BioDiem Ltd, H2 2016
  • Neisseria gonorrhoeae Infections - Pipeline by Biolytics Pharma, H2 2016
  • Neisseria gonorrhoeae Infections - Pipeline by Debiopharm International SA , H2 2016
  • Neisseria gonorrhoeae Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Neisseria gonorrhoeae Infections - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Neisseria gonorrhoeae Infections - Pipeline by Merck & Co., Inc., H2 2016
  • Neisseria gonorrhoeae Infections - Pipeline by Paratek Pharmaceuticals, Inc., H2 2016
  • Neisseria gonorrhoeae Infections - Pipeline by Recce Pty Ltd, H2 2016
  • Neisseria gonorrhoeae Infections - Pipeline by Redx Pharma Plc, H2 2016
  • Neisseria gonorrhoeae Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2016
  • Neisseria gonorrhoeae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Neisseria gonorrhoeae Infections - Dormant Projects, H2 2016
  • Neisseria gonorrhoeae Infections - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Neisseria gonorrhoeae Infections, H2 2016
  • Number of Products under Development for Neisseria gonorrhoeae Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top